UNC 0631
-
UNC 0631
structure -
-
CAS No:
1320288-19-4
-
Formula:
C37H61N7O2
-
Chemical Name:
UNC 0631
-
Synonyms:
UNC 0631;UNC0631/UNC-0631;N-[1-(CyclohexylMethyl)-4-piperidinyl]-2-[hexahydro-4-(1-Methylethyl)-1H-1,4-diazepin-1-yl]-6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinaMine;N-[1-(Cyclohexylmethyl)-4-piperidinyl]-2-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinamineUNC0631;UNC 0631, >=98%;N-(1-(cyclohexylmethyl)piperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine
- Categories:
-
CAS No:
Description
UNC 0631 is a potent G9a inhibitor with IC50 value of 4 nM.IC50 value: 4 nM [1]Target: G9aUNC 0631, which had high in vitro potency versus G9a and improved lipophilicity, was highly potent (IC50 < 0.06 μM) in reducing H3K9me2 levels in MDA-MB-231 cells and had low cell toxicity. In particular, compounds 7 was more potent than compound 5 and had a similar tox/function ratio in MDAMB-231 cells. UNC 0631 showed excellent separation of functional potency versus cell toxicity in MDA-MB-231 ce
Characteristics
72.46000
6.29
1.114±0.06 g/cm3(Predicted)
763.4±70.0 °C(Predicted)
415.5±35.7 °C
1.579
Drug Information
N-(1-(cyclohexylmethyl)piperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine
UNC 0631 Use and Manufacturing
UNC0631 is a potent and selective inhibitor of G9a activity in vitro (IC50 = 4 nM) and G9a/GLP-mediated dimethylation of histone 3 on lysine 9 in MDA-MB-231 cells (IC50 = 25 nM). It potently inhibits G9a/GLP activity in a variety of cancer cell lines as well as in the human fetal lung IMR-90 cell line.[Cayman Chemical]
Computed Properties
Molecular Weight:635.9
XLogP3:7.4
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:9
Rotatable Bond Count:12
Exact Mass:635.48867421
Monoisotopic Mass:635.48867421
Topological Polar Surface Area:69.2
Heavy Atom Count:46
Complexity:861
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Latest News on UNC 0631
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
UNC 669
1314241-44-5
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141 Formula
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Structure
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
What is C-REACTIVE PROTEIN FRAGMENT 77-82
130349-01-8
-
What is Sildenafil
139755-83-2